The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment
Background: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. Aims: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. Patients & methods: Generalized estimati...
| Autor principal: | Sortica, Vinicius Albuquerque |
|---|---|
| Outros Autores: | Lindenau, Juliana D, Cunha, Maristela G, Ohnishi, Maria D. O, Ventura, Ana Maria Revoredo da Silva, Santos, ?ndrea K. C Ribeiro dos, Santos, Sidney E. B, Guimar?es, Luciano S. P, Hutz, Mara H |
| Grau: | Artigo |
| Idioma: | eng |
| Publicado em: |
Future Medicine
2017
|
| Assuntos: | |
| Acesso em linha: |
http://patua.iec.gov.br/handle/iec/2502 |
| Resumo: |
|---|
|
Background: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. Aims: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. Patients & methods: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients. Results: An effect of CYP2C8 low-activity alleles on treatment was observed (p = 0.01). From baseline to first day of treatment, wild-type individuals achieved greater reduction of gametocytes than low-activity allele carriers. CYP2C9 and CYP3A5 genes showed a trend for gametocytemia and parasitemia clearance rates. Conclusion: Future studies should be performed to access the extent of CYP2C8, CYP2C9 and CYP3A5 gene polymorphisms influence on cloroquine/primaquine treatment. |